Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase Ia, Multicenter, Open-Label, Single-Dose, Dose-Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravitreal Injections of FCFD4514S in Patients With Geographic Atrophy

NCT00973011 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT00973011
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00973011 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase Ia, Multicenter, Open-Label, Single-Dose, Dose-Escalation Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Intravitreal Injections of FCFD4514S in Patients With Geographic Atrophy
Lead sponsor
Genentech, Inc.
Phase
Phase 1
Overall status
Completed
Start date
September 30, 2009
Completion date
July 31, 2010
Enrollment
18 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

geographic atrophy